Andrea Miyahira hosts Marina Sharifi about a multiomic profiling study of metastatic castration-resistant prostate cancer using circulating tumor cells, ctDNA, and RNA sequencing.

Zachary Klaassen discusses the NureCombo Trial with Chiara Mercinelli, examining neoadjuvant therapy for muscle-invasive bladder cancer. This phase II trial investigated nab-paclitaxel plus nivolumab ...

TALAPRO-2 trial results, talazoparib enzalutamide combination, HRR mutations prostate cancer, PARP inhibitor mCRPC, Differential Treatment Responses Across HRR Gene Alterations in Prostate Cancer with ...

PSMA and Beyond 2025 CAR-T and Bispecific antibodies targeting PSMA, Poseida trial, neuroendocrine prostate cancer, STEAP-1.

PSMA and Beyond 2025 CA-IX in renal cell cancer (RCC), ZIRCON, kidney cancer, stage migration for RCC, REDECT trial, renal mass biopsy, girentuximab.

SNMMI 2025, post-177Lu therapy, WB SPECT/CT, WB SPECT/CT Studies Post Lu 177 Therapy, 177Lu-PSMA SPECT, StarGuide scanner, 177Lu-PSMA-617 radiopharmaceutical therapy.

Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment.

Risk factors for low-risk prostate cancer: A retrospective cohort study within the FinRSPC trial. July 18, 2025 Unplanned hospitalization among advanced prostate cancer patients by diabetes status-a ...

AUA 2025, Metastatic Renal Cell Carcinoma (mRCC), Maximal Evaluable Lesion Size in Patients with Metastatic Renal Cell Carcinoma, Nivolumab plus Ipilimumab Combination Therapy, nivolumab, ipilimumab, ...

ASCO 2025, prostate cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), XALute Study, Xaluritamig, Cabazitaxel, Xaluritamig versus Cabazitaxel or Second Androgen Receptor-Directed Therapy ...

SNMMI 2025 utility of the PROSTest to predict response to 177Lu-PSMA therapy in metastatic castration resistant prostate cancer (mCRPC), blood-based 27-marker gene mRNA expression machine ...

SNMMI 2025 clinical value of the PROSTest to detect biochemical recurrence in prostate cancer, PSMA-PET/CT, PSMA-PET/CT imaging, PROSTest, biochemical recurrence in prostate cancer.